What We Do

At CrownBio we enable our clients to make rapid, vital, and scientifically sound decisions as to which compounds to advance into the clinic


Enabling Rapid, Scientifically-Sound Decision Making

Our portfolio of Translational Platforms for oncology and inflammation provide insight and understanding about a drug's efficacy, pharmacological profile and patient response profile, reducing failure in the clinic, and supporting the selection of the right patients for the right therapy.

CrownBio’s fast-paced R&D programs are yielding novel, yet well-validated models, at the cutting-edge of disease research. Our unique MuPrime™ models, as well as human target expressing models (HuGEMM™) and hematopoietic stem cell (HSC) – patient-derived xenograft (PDX) models are leading the way in advanced immuno-oncology.

Drive Your Next Clinical Success

Read why PDX models and their use in human-surrogate Phase II-like trials are changing the paradigm for oncology drug development and biomarker discovery today.

We’re inspired to help our clients. Let’s talk about how we can help you.

Discuss Your Project